A clinical-stage biotechnology company developing gene and cell therapies for cancer, autoimmune disorders, and infectious diseases using proprietary gene delivery and control technologies. Its pipeline includes immuno-oncology candidates such as PRGN-2012 and other programs designed to modulate the...
1 member of Congress has disclosed 1 trade in Precigen, Inc. (PGEN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-04-01 | Tom Malinowski | buy | $1K – $15K |